Search

Real-World Data

Analysing the impact of the FreeStyle Libre 2 Portfolio on the lives of real users

real world data

Outcomes for people with diabetes

The FreeStyle Libre 2 Portfolio is making a real impact on outcomes for people with diabetes.

Increases Time in Range1

Improves quality of life2

Reduces hypoglycaemia1,3

Decreases HbA1c4

Real-World Data

More frequent use of the FreeStyle Libre 2 systems* increases Time in Range5

Comparing two groups from lowest to highest scan rate8, patients who scanned more frequently using the FreeStyle Libre systems* spent 43% more Time In Range.

5.8 million

FreeStyle Libre 2 sensors

1.71 billion

hours of glucose readings

43%

more Time In Range

(70-180 mg/dL) from 11.7 to 16.8 hours per day5 (p<0.001)

Frequent use of the FreeStyle Libre 2 system also resulted in patients spending 26% less Time Below Range (<54 mg/dL)5

The FreeStyle Libre 2 system is clinically proven to significantly reduce hypoglycaemia in T1D1 and T2D3 patients

Increased testing frequency is sustained over time with the FreeStyle Libre 2 system.9

Impact Study1: T1D Patients

Hypoglycaemia is defined as <70 mg/dL.

Impact Study showing how the FreeStyle Libre system positively affects people with type 1 diabetes

Replace Study3: T2D Patients

Impact Study showing how the FreeStyle Libre system positively affects people with type 1 diabetes
img
img

Clinical Evidence

Clinical benefits for a broad range of T1D and
T2D patients.

EXPLORE CLINICAL EVIDENCE

References & Disclaimers

Images are for illustrative purposes only. Not real patient, data or healthcare professional.

* FreeStyle Libre systems refers to the FreeStyle Libre 2 system

1. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.

2. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809.

3. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1): 55-73.

4. Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42(7):1178-1184. 2020;43(2):389-397.

5. Lang J, Jangam S, Dunn T, Hayter G. Expanded real-world use reaffirms strong correlation between scanning frequency of flash glucose monitoring and glucose control [Poster 972]. Diabetes. 2019;68(suppl 1). https://doi.org/10.2337/db19-972-P.

6. Deshmukh H, et al. Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Diabetes Care 2020;43:2153–2160.

7. From baseline 67.2 mg/dL HbA1c across the entire study population.

8. Comparing 2 groups from lowest to highest scan rate (3.6 and 39.5 scans/day).

9. Jangam S, Dunn T, Xu Y, Hayter G, Ajjan R. Flash glucose monitoring improves glycemia in higher-risk patients: a longitudinal, observational study under real-life settings. BMJOpen Diab Res Care 2019;7:e000611. DOl:10.1136/bmjdrc-2018-000611.

Cookie Policy

FreeStyle Libre uses cookies to give you the best possible service. By using our website, you consent to the use of cookies. 

Data protection

Why FreeStyle Libre Systems?
FreeStyle Portfolio
Scientific Evidences
Educational Resources
News Corner
Help and Support

© 2025 Abbott. FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorisation of Abbott Laboratories, except to identify the product or services of the company. This website and the information contained herein is intended for use by residents in United Arab Emirates. Images and simulated data for illustrative purposes only. Not real patient or data.
ADC-82800 v1.0 09/23

Disclaimer

This is a product-specific website intended for HCPs of UAE only. If you live in another country, please contact your local Abbott office to obtain the correct product information for your country of residence.